Jeremy J. Glynn

Engineering an Endothelialized Vascular Graft: A Rational Approach to Study Design in a Non-Human Primate Model

After many years of research, small diameter, synthetic vascular grafts still lack the necessary biologic integration to perform ideally in clinical settings. Endothelialization of vascular grafts has the potential to improve synthetic graft function, and endothelial outgrowth cells (EOCs) are a promising autologous cell source. Yet no work has established the link between endothelial cell functions and outcomes of implanted endothelialized grafts. This work utilized steady flow, oscillatory flow, and tumor necrosis factor stimulation to alter EOC phenotype and enable the formulation of a model to predict endothelialized graft performance. To accomplish this, EOC in vitro expression of coagulation and inflammatory markers was quantified. In parallel, in non-human primate (baboon) models, the platelet and fibrinogen accumulation on endothelialized grafts were quantified in an ex vivo shunt, or the tissue ingrowth on implanted grafts were characterized after 1mth. Oscillatory flow stimulation of EOCs increased in vitro coagulation markers and ex vivo platelet accumulation. Steady flow preconditioning did not affect platelet accumulation or intimal hyperplasia relative to static samples. To determine whether in vitro markers predict implant performance, a linear regression model of the in vitro data was fit to platelet accumulation data—correlating the markers with the thromboprotective performance of the EOCs. The model was tested against implant intimal hyperplasia data and found to correlate strongly with the parallel in vitro analyses. This research defines the effects of flow preconditioning on EOC regulation of coagulation in clinical vascular grafts through parallel in vitro, ex vivo, and in vivo analyses, and contributes to the translatability of in vitro tests to in vivo clinical graft performance.

Crosslinking decreases the hemocompatibility of decellularized, porcine small intestinal submucosa.

Decellularized tissues have been widely used as scaffolds for biomedical applications due to their presentation of adhesion peptide sequences and growth factors, which facilitate integration with surrounding tissue. One of the most commonly used decellularized tissues is derived from porcine small intestinal submucosa (SIS). In some applications, SIS is crosslinked to modulate the mechanical properties or degradation rate of the scaffold. Despite the widespread use of SIS, there has been no mechanistic characterization of blood reactions with SIS, or how crosslinking affects these reactions. Therefore, we characterized the effect of SIS and carbodiimide-crosslinked SIS (cSIS) on plasma coagulation, including targeted assessments of the intrinsic and extrinsic coagulation pathways, and thrombus formation using flowing whole blood. SIS inhibited plasma coagulation initiated by recalcification, as well as low concentrations of thrombin or tissue factor. SIS prolonged the activated partial thromboplastin time by 14.3 ± 1.54s, indicating inhibition of the intrinsic coagulation pathway. Carbodiimide crosslinking abrogated all anticoagulant effects of SIS, as did heparinase I and III treatment, suggesting that heparin and heparan sulfate are predominantly responsible for SIS anticoagulant effects. Inhibiting contact activation of the intrinsic pathway prevented cSIS-mediated coagulation. When tubular SIS devices were connected to a nonhuman primate arteriovenous shunt loop, which enables whole blood to flow across devices without the use of anticoagulants, SIS demonstrated remarkably limited platelet accumulation and fibrinogen incorporation, while cSIS initiated significantly higher platelet and fibrinogen accumulation. These results demonstrate that SIS is a thromboresistant material and crosslinking markedly reduces the hemocompatibility of SIS.

Thrombotic responses of endothelial outgrowth cells to protein-coated surfaces.

There is significant clinical need for viable small-diameter vascular grafts. While there are many graft biomaterials in development, few have been clinically successful. Evaluation of grafts with a clinically relevant model is needed to drive development. This work examined extracellular matrix coatings on the thrombotic phenotype of endothelial outgrowth cells (EOCs). EOCs were tested on flat plates and tubular grafts. Flat plate studies examined collagen I, collagen IV, fibronectin and α-elastin coatings. EOCs attached or proliferated more readily on collagen I and fibronectin surfaces as determined by total DNA. The production of activated protein C (APC) by EOCs was also dependent on the surface coating, with collagen I and fibronectin displaying a higher activity than both collagen IV and α-elastin on flat plate studies. Based on these results, only collagen I and fibronectin coatings were tested on expanded polytetrafluoroethylene (ePTFE) in the ex vivo model. Tubular samples showed significantly greater tissue factor pathway inhibitor gene expression on collagen I than on fibronectin. Platelet adhesion was not significantly different, but EOCs on collagen I produced significantly lower APC than on fibronectin, suggesting that differences exist between the flat plate and tubular cultures. Overall, while the hemostatic phenotype of EOCs displayed some differences, cell responses were largely independent of the matrix coating. EOCs adhered strongly to both fibronectin- and collagen-I-coated ePTFE grafts under ex vivo (100 ml/min) flow conditions suggesting the usefulness of this clinically relevant cell source, testing modality, and shunt model for future work examining biomaterials and cell conditioning before implantation.

The OregonHeart Total Artificial Heart: Design and Performance on a Mock Circulatory Loop

Widespread use of heart transplantation is limited by the scarcity of donor organs. Total artificial heart (TAH) development has been pursued to address this shortage, especially to treat patients who require biventricular support. We have developed a novel TAH that utilizes a continuously spinning rotor that shuttles between two positions to provide pulsatile, alternating blood flow to the systemic and pulmonary circulations without artificial valves. Flow rates and pressures generated by the TAH are controlled by adjusting rotor speed, cycle frequency, and the proportion of each cycle spent pumping to either circulation. To validate the design, a TAH prototype was placed in a mock circulatory loop that simulates vascular resistance, pressure, and compliance in normal and pathophysiologic conditions. At a systemic blood pressure of 120/80 mm Hg, nominal TAH output was 7.4 L/min with instantaneous flows reaching 17 L/min. Pulmonary artery, and left and right atrial pressures were all maintained within normal ranges. To simulate implant into a patient with severe pulmonary hypertension, the pulmonary vascular resistance of the mock loop was increased to 7.5 Wood units. By increasing pump speed to the pulmonary circulation, cardiac output could be maintained at 7.4 L/min as mean pulmonary artery pressure increased to 56 mm Hg while systemic blood pressures remained normal. This in vitro testing of a novel, shuttling TAH demonstrated that cardiac output could be maintained across a range of pathophysiologic conditions including pulmonary hypertension. These experiments serve as a proof-of-concept for the design, which has proceeded to in vivo testing.

Bioactive Anti-Thrombotic Modification of Decellularized Matrix for Vascular Applications

The decellularized matrix derived from porcine small intestinal submucosa (SIS) is a widely used biomaterial being investigated for numerous applications. Currently, thrombus deposition and neointimal hyperplasia have limited the use of SIS in some vascular applications. To limit these detrimental processes, this work applies bioactive, endothelial-inspired properties to the material. SIS is modified with the endothelial cell membrane protein thrombomodulin and the glycosaminoglycan heparin to facilitate protein C activation and anticoagulant activity, respectively. Modifying SIS with thrombomodulin alone enables robust activated protein C (APC) generation, and thrombomodulin activity is maintained after prolonged exposure to fluid shear and blood plasma. Heparin-modified SIS has a potent anticoagulant activity. When both modifications are applied sequentially, SIS modified first with thrombomodulin then with heparin retains the full activity of each individual modification. Tubular SIS devices are connected to a baboon arteriovenous shunt to quantify thrombus deposition on these materials. After being exposed to flowing whole blood for 60 min, SIS devices modified first with thrombomodulin then with heparin have significantly less platelet accumulation compared to unmodified SIS devices. These studies demonstrate that modifying SIS with thrombomodulin and heparin confers APC generation and anticoagulant activity that results in reduced thrombogenesis.

Steady Flow Preconditioning of Endothelial Outgrowth Cells on Ex Vivo and In Vivo ePTFE Grafts

Endothelialization of vascular graft materials is a promising approach for improving the in vivo performance of vascular grafts, particularly for small diameter applications of less than 4 mm. The ability to incorporate a native endothelium onto a graft may reduce the thrombosis and intimal hyperplasia that limits long-term clinical success of these small diameter grafts. Endothelial outgrowth cells (EOCs), which are isolated from whole blood and expand rapidly in vitro, provide an autologous cell source capable of developing into a biologically active endothelial layer. A preconditioning step may enhance EOCs’ performance on vascular grafts. Mature endothelial cells, isolated from vascular walls, are known to decrease expression of pro-thrombotic and pro-inflammatory markers when exposed to steady fluid shear stress, compared to cells under disturbed flow conditions or static culture. This study examined the hypothesis that steady flow preconditioning of EOCs reduces their in vitro markers of thrombosis and inflammation, reduces platelet and fibrin accumulation on EOC–coated ePTFE grafts in an ex vivo shunt, and reduces initial hyperplasia on EOC–coated ePTFE grafts in an in vivo graft implant. This work was performed using well-established, non-human primate models for testing EOC-coated ePTFE grafts ex vivo and in vivo. These conditions represent a clinically-relevant cell source and biomaterial for determining the effects of fluid shear stress preconditioning on graft performance.Copyright

Contrasting the thrombotic phenotype of donor-matched endothelial outgrowth cells and endothelial cells

Despite the increasing burden of cardiovascular disease, vascular tissue engineering strategies have had limited success in achieving long-term patency in grafts less than 4 mm in diameter. Graft failure is often due to occlusion by thrombosis or intimal hyperplasia. Recognizing the capacity of endothelial cells (ECs) to properly coordinate these processes in vivo, much research has investigated the use of ECs to line the lumens of vascular grafts to improve patency (Zilla et al. 1994). However, the limited availability of autologous ECs and the donor site morbidity resulting from EC harvest has limited the clinical potential of these cellularized constructs.Copyright

Front & Back Matter

Each paper needs an abstract of a maximum of 250 words summarizing the essential new information communicated. Subheadings: Introduction; Materials and Methods; Results; Discussion. List of Abbreviations: Provide a list of the abbreviations used in your paper. Please list them on a separate page of the manuscript. The list will be printed as a footnote at the bottom of the first page of your article. Footnotes: With the exception of the list of abbreviations, footnotes should be avoided. When essential, they are numbered consecutively and typed at the foot of the appropriate page. Nomenclature: The nomenclature used should conform, wherever possible, to the current edition of the Nomina Anatomica (Terminologia Anatomica), Nomina Anatomica Veterinaria, or to the Nomina Anatomica Avium. Tables and illustrations: Tables and illustrations (both numbered in Arabic numerals) should be prepared as separate files. Tables require a heading and figures a legend, prepared on a separate page. Please only use scale bars to indicate magnifications of the illustrations. Due to technical reasons, figures with a screen background should not be submitted. When possible, group several illustrations on one block for reproduction (max. size 180  223 mm) or provide crop marks. Each illustration must be labelled with its number and the author’s name. B/w half-tone and color illustrations must have a final resolution of 300 dpi after scaling (final size), line drawings one of 800–1200 dpi. Figure files must not be embedded in a document file but submitted separately (see detailed instructions at www.karger.com/cto). Color illustrations: During the review process, the decision will be made as to which color illustrations of a manuscript can be reproduced free of charge. Authors will be informed of this at the time of acceptance of their paper. Otherwise, these illustrations will be reproduced at the author’s expense. Up to 6 color illustrations per page can be integrated into the text at the special price of CHF 800.– per page. References: References in the text should be made by author’s name followed by the year of publication, arranged chronologically, then alphabetically. When there are more than two authors, use the first author’s name and et al. When references are made to more than one paper by the same author, published in the same year, designate them as a, b, c, etc. The list of references should include only those publications which are cited in the text. Material submitted for publication but not yet accepted may be cited in the text as ‘unpublished data’ but must not be included in the reference list. In the list of references, arrange references alphabetically listing all authors, then year of publication. Preferably, please cite all authors. Abbreviate journal names according to Index Medicus. Examples (a) Papers published in periodicals: Robinson, C.M., D. O’Dee, T. Hamilton, G.J. Nau (2010) Cytokines involved in interferon-γ production by human macrophages. J Innate Immun 2: 56–65. (b) Papers published only with DOI numbers: Konstantinou, G.N., P.J. Bousquet, T. Zuberbier, N.G. Papadopoulos: The longest wheal diameter is the optimal measurement for the evaluation of skin prick tests. Int Arch Allergy Immunol DOI: 10.1159/000250443. (c) Monographs: Matthews, D.E., V.T. Farewell (2007) Using and Understanding Medical Statistics, ed 4, revised. Basel, Karger. (d) Chapters published in edited books: Li, L., V. Boussiotis (2009) Control and regulation of peripheral tolerance in allergic infl ammatory disease: therapeutic consequences; in Blaser, K. (ed): T Cell Regulation in Allergy, Asthma and Atopic Skin Diseases. Chem Immunol. Basel, Karger, vol 94, pp 178–188. Further details: Authors may consult the ‘Guide to Writing Articles in English’ by R. O’Rahilly (Acta Anat 131: 1–2, 1988). Digital Object Identifier (DOI) S. Karger Publishers supports DOIs as unique identifiers for articles. A DOI number will be printed on the title page of each article. DOIs can be useful in the future for identifying and citing articles published online without volume or issue information. More information can be found at www.doi.org. Supplementary Material Supplementary material is restricted to additional data that are not necessary for the scientific integrity and conclusions of the paper. Please note that all supplementary files will undergo editorial review and should be submitted together with the original manuscript. The Editors reserve the right to limit the scope and length of the supplementary material. Supplementary material must meet production quality standards for